CD8A and infection: Alternatively, anti-IFNAR1 mAb treatment may help correct a functionally overactive innate immune response, such as that occurring during the chronic stage of LCMV clone 13 infection, where the IFNAR1 blockade improved CD8+ T-cell viral control (53, 54).